New RAPID Pathway Aims to Expedite Medicare Device Coverage
The Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) have introduced a new initiative, the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, to expedite Medicare coverage for specific medical devices that qualify as breakthrough devices by the FDA. This initiative aims to reduce the delay between FDA market authorization and Medicare coverage decisions by ensuring earlier collaboration between the two agencies.
The RAPID pathway seeks to streamline the process for high-risk medical devices, including Class III and select Class II devices, to gain Medicare coverage upon FDA approval. These devices must be involved in an Investigational Device Exemption (IDE) study focusing on clinical outcomes relevant to Medicare beneficiaries. RAPID intends to help manufacturers by aligning clinical evidence requirements for both FDA and CMS reviews, historically approached separately.
According to the CMS and FDA announcement, RAPID could be particularly advantageous for breakthrough devices requiring comprehensive evidence for approval, such as new therapeutic and diagnostic technologies for serious health conditions affecting the Medicare demographic. Early engagement with CMS and FDA is crucial for device sponsors to leverage this pathway effectively, ensuring their studies meet necessary safety, effectiveness, and coverage criteria.
The anticipated pathway will allow CMS to issue a proposed National Coverage Determination (NCD) on the same day a device receives FDA market authorization. This aims to significantly reduce the current timeline, potentially enabling Medicare reimbursement within two months, rather than the prolonged periods previously experienced.
CMS will maintain existing coverage pathways alongside RAPID, allowing sponsors to choose the pathway that best suits their device and business strategy. Importantly, RAPID does not alter the standards used by the FDA for market approval nor those applied by CMS for coverage determination.
This development represents CMS’ latest effort to address the coverage of breakthrough devices, following previous initiatives such as the Medicare Coverage for Innovative Technologies (MCIT) program and the Transitional Coverage for Emerging Technologies (TCET) program. The TCET initiative will be paused as resources shift toward RAPID's implementation.
Additionally, legislative interest in improving coverage certainty for breakthrough devices could influence the framework within which RAPID functions. For instance, Congress is considering the "Ensuring Patient Access to Critical Breakthrough Products Act," proposing a transitional coverage period and mandating timely coverage decisions.
In conjunction with RAPID, CMS proposed changes to how new technologies qualify for specific payment provisions under Medicare's Inpatient Prospective Payment System (IPPS) and Outpatient Prospective Payment System (OPPS). Future regulations may require breakthrough devices to demonstrate clinical improvement without automatic favorable treatment, affecting reimbursement but distinct from coverage considerations under RAPID.
As the industry awaits the full details of RAPID’s structure, stakeholders are encouraged to participate in the forthcoming public comment period following the proposal’s publication in the Federal Register. This engagement will be essential for informing the pathway's final design and addressing any operational concerns related to implementation.